NICE rejects arthritis drug in draft advice

Golimumab has not been recommended for use in treating psoriatic arthritis, under draft guidance issued by NICE.

Psoriatic arthritis (Photograph: SPL)

The drug is licensed for use alone, or in combination with methotrexate, for active and progressive psoriatic arthritis in adult patients when previous therapy has been inadequate.

It is also licensed for limited use in the treatment of rheumatoid arthritis and ankylosing spondylitis.

NICE has made the recommendation because research shows golimumab is not more cost-effective than other available options. A spokesman said: 'NICE recommends adalimumab, etanercept and infliximab for the treatment of psoriatic arthritis in people with peripheral arthritis. The cost-effectiveness analyses found that golimumab was not the most cost-effective of the available options currently recommended by NICE.'

A secondary reason for the advice was uncertainty about possible side-effects of the drug, as a long-term follow-up on adverse outcomes is ongoing.

The spokesman added that economic modelling based on evidence about golimumab had shown the drug may be less cost-effective than etanercept, and 'could not be considered a good use of NHS resources'.

The drug's manufacturer MSD said: 'MSD strongly believes that any restrictions on access to this treatment would inhibit patient choice for the treatment of this disabling and chronic disease.'

The draft guidance is open to consultation.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Just published

GMC sign

Gaps in GMC referral and exam pass rates for ethnic minority doctors falling, says GMC

Gaps in fitness to practise referrals and exam pass rates between doctors from white...

Pharmacy shelves

Menopause prescribing advice updated as HRT shortage continues

The British Menopause Society has recommended alternative options for prescribers...

GP sign

Using IIF cash to top up staff pay risks major gap in practice finances, warn accountants

GP practices could face a major cash shortfall in 2024/25 if they use investment...

Paxlovid – one of the treatments available for COVID-19

GPs could play bigger role in prescribing COVID-19 treatments from end of June

GPs could play a greater role in prescribing COVID-19 treatments to patients at risk...

Physiotherapist works with patient

Is the government right to claim its 26,000 additional roles target has been met?

Prime minister Rishi Sunak claimed last month that the government had met its manifesto...

Statement of fitness for work

GP training: Tips for completing FIT notes

GP trainer Dr Pipin Singh provides advice for trainees on how to complete fit notes,...